4D MOLECULAR THERAPEUTICS IN

4D Molecular Therapeutics stock dips 3.66% to $12.20, 20.53% down YoY. Insider activity, a 200‑day SMA near support, and a growing genetic‑disease pipeline signal cautious upside potential.

4d Molecular Therapeutics (FDMT) gains 6.59% after insider activity and a bullish 200‑day MA, highlighting potential upside for biotech investors.